InvestorsHub Logo
Followers 142
Posts 22193
Boards Moderated 2
Alias Born 02/01/2013

Re: JohnCM post# 1095

Friday, 03/27/2020 7:40:20 AM

Friday, March 27, 2020 7:40:20 AM

Post# of 2339
Yeah, great stuff John and why we like you ;)

As far as that little boat bouncin' around in the choppy water

Big move yesterday!, lol... damn insiders knew this was coming:

..today filed its audited Year-end Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2019.

"2019 was a pivotal year for Cardiol Therapeutics," stated David Elsley, President and CEO. "We attracted industry-leading talent to our management team, world class stewardship and experience to our Board of Directors, and global thought leaders in cardiology to the Steering Committee for our Phase 2 international trial in acute myocarditis. We also established the commercial infrastructure and pharmaceutical supply chain necessary to support the commercial launch of the purest cannabidiol in the world - a product specifically formulated for consistency, stability, and purity to meet the needs of millions of people who should not be exposed to THC.

The Company's most significant achievement to date followed our 2019 fiscal year end with the signing of an exclusive supplier agreement with Canada's largest pharmacy retailer, Shoppers Drug Mart, to supply our pharmaceutical cannabidiol formulation to patients nationwide. Formulated purely for medical purposes and manufactured under the most stringent quality standards set by the pharmaceutical industry, the commercialization of our pharmaceutical high purity, THC free (<5ppm) cannabidiol oil aims to address a growing market need for patients who should not be exposed to THC.


  https://web.tmxmoney.com/article.php?newsid=5007524781028879&qm_symbol=CRDL

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.